Ladenburg Thalmann & Co. Inc.
640 Fifth Avenue, 4th Floor
New York, New York 10019
November 3, 2022
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, DC 20549
| Re: | NeuroBo Pharmaceuticals, Inc. | |
| Registration Statement on Form S-1 (Registration No. 333-267482) | ||
| Concurrence in Acceleration Request |
Ladies and Gentlemen:
Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by NeuroBo Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on November 4, 2022, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.
| Very truly yours, | ||
| LADENBURG THALMANN & CO. INC. | ||
| By: | /s/ Nicholas Stergis | |
| Name: Nicholas Stergis | ||
| Title: Managing Director | ||